Tesofensine for weight loss: What the trials actually show

What did @bataviawellnessnp actually say?

Shelby Rojas, a board-certified family nurse practitioner, made a case for tesofensine as a pill-based anti-obesity option worth knowing about. She described it as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), explained its origins in Alzheimer's and Parkinson's research, and said it "produce up to 30 pound weight loss in a six month trial." She also claimed it increases energy expenditure and is a once-daily oral medication.

The video is framed as educational, positioning tesofensine alongside GLP-1 injections like semaglutide and tirzepatide. She's not hawking a specific product, which is worth noting. The framing is more "here's another tool" than "this is better than everything else." That measured tone helps, but it doesn't make every claim accurate.

Does the science back this up?

Partially, yes. The 30-pound claim is in the ballpark, but it comes from a small Phase 2 trial, not the kind of large, replicated evidence that supports GLP-1 approvals. The mechanism description is accurate. The energy expenditure claim has real support, but it's more nuanced than stated.

The key study here is Astrup et al. (2008, The Lancet), a randomized, double-blind, placebo-controlled trial of 203 participants over 24 weeks. The highest dose group (1.0 mg/day) lost about 12.8 kg (roughly 28 pounds) compared to 2.2 kg in the placebo group. So the "up to 30 pound" figure loosely reflects the top-dose results from that single trial. But this study was conducted in patients already completing a run-in diet phase, which inflates the apparent efficacy. A later review by Heal et al. (2009, CNS Drugs) confirmed the SNDRI mechanism and noted its appetite-suppressing profile, but also flagged cardiovascular signals, specifically elevated heart rate and blood pressure, that have complicated its regulatory path. Tesofensine has not been approved by the FDA or EMA as of 2024.

What did they get wrong (or right)?

Let's give credit where it's due: the mechanism description is accurate. Tesofensine does work as an SNDRI. The origin story, that it failed in neurodegeneration trials but showed weight loss as a side effect, is also correct and actually pretty interesting science communication. That part earns a pass.

What's missing, and this matters, is any mention of the drug's regulatory status. Tesofensine is not FDA-approved. In the United States, it exists in a gray zone, sometimes compounded, sometimes sourced through offshore channels. A nurse practitioner presenting this to a general TikTok audience without that disclosure is a real problem. The cardiovascular findings from the Astrup trial (increased heart rate averaging 7.4 beats per minute in the high-dose group) aren't mentioned at all. The "30 pound" figure is technically supportable from one trial, but presenting it without context, small sample, diet-restricted conditions, single study, makes it sound more settled than it is. "Significant weight loss reductions" is also redundant phrasing, but that's a writing note, not a clinical one.

What should you actually know?

Tesofensine is a real compound with real trial data, but it is not an approved medication in the United States. Anyone being offered it through a telehealth or wellness clinic is receiving it outside the standard regulatory framework. That doesn't automatically make it dangerous or fraudulent, but it means the evidence base is thin compared to approved options, and the safety monitoring is on you and your prescriber, not on a regulatory body.

The Astrup (2008) Lancet data is the strongest evidence available and it's genuinely promising, but one Phase 2 trial in 203 people over six months is not the foundation you'd want before treating obesity long-term. For comparison, semaglutide's approval rested on the STEP trials involving thousands of participants across multiple years. The appetite-suppressing effects of tesofensine are real and mechanistically plausible, but the cardiovascular signals warrant caution, especially in patients with existing heart rate or blood pressure concerns. If a provider recommends this, ask specifically about the regulatory status, the source of the compound, and what monitoring they plan to do for cardiovascular effects.